PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsTeriparatide
Parathar, Forsteo(teriparatide)
Bonsity, Forsteo, Forteo, Kauliv, Livogiva, Movymia, Parathar, Sondelbay, Teriparatide, Terrosa (teriparatide) is a protein pharmaceutical. Teriparatide was first approved as Parathar on 1987-12-23. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis and postmenopausal osteoporosis. The pharmaceutical is active against parathyroid hormone/parathyroid hormone-related peptide receptor. In addition, it is known to target parathyroid hormone 2 receptor.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Bonsity, Forteo, Teriparatide (discontinued: Forteo, Parathar)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Teriparatide
Tradename
Company
Number
Date
Products
BONSITYAlvogenN-211939 RX2019-10-04
1 products
FORTEOEli LillyN-021318 RX2008-06-25
1 products, RLD, RS
Show 1 discontinued
Teriparatide acetate
Tradename
Company
Number
Date
Products
PARATHARSanofiN-019498 DISCN1987-12-23
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
bonsityNew Drug Application2025-06-01
forteoNew Drug Application2025-06-03
teriparatideANDA2025-07-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
postmenopausal osteoporosisEFO_0003854D015663—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Teriparatide, Forteo, Lilly
75173342025-03-25DP
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H05: Calcium homeostasis
— H05A: Parathyroid hormones and analogues
— H05AA: Parathyroid hormones and analogues
— H05AA02: Teriparatide
HCPCS
Code
Description
J3110
Injection, teriparatide, 10 mcg
Clinical
Clinical Trials
195 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OsteoporosisD010024EFO_0003882M81.01029182628108
Postmenopausal osteoporosisD015663EFO_0003854—551016742
Metabolic bone diseasesD001851——1724317
Bone fracturesD050723EFO_0003931T14.81533313
Spinal fracturesD016103EFO_0003902S12——1135
Stress fracturesD015775—M84.3——2114
Spinal cord injuriesD013119EFO_1001919——3—1—4
Chronic kidney disease-mineral and bone disorderD012080EFO_1001152N25.0——1113
Osteogenesis imperfectaD010013—Q78.0—1—2—3
Wounds and injuriesD014947—T14.8—2—1—3
Show 13 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypoparathyroidismD007011—E20196—317
Osteoporotic fracturesD058866———31—48
Endocrine system diseasesD004700EFO_0001379E34.9213——6
Hip fracturesD006620EFO_0003964S72.00—21—25
HypocalcemiaD006996HP_0002901E83.51—31——4
Parathyroid diseasesD010279—E21.5—13——4
Secondary hyperparathyroidismD006962EFO_1001173———1—12
AnorexiaD000855—R63.0—11——2
Anorexia nervosaD000856EFO_0004215F50.0—11——2
Femoral neck fracturesD005265EFO_1001792S72.00——2——2
Show 6 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bone diseasesD001847—M89.912——14
Knee osteoarthritisD020370EFO_0004616M17—2——13
Musculoskeletal diseasesD009140——11———2
Colles' fractureD003100—S52.53—2———2
Myeloid leukemia acuteD015470—C92.0—1———1
Primary myelofibrosisD055728—D47.4—1———1
LymphomaD008223—C85.9—1———1
Precursor cell lymphoblastic leukemia-lymphomaD054198—C91.0—1———1
B-cell chronic lymphocytic leukemiaD015451—C91.1—1———1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340——1———1
Show 17 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———4————4
HyperparathyroidismD006961EFO_0008506E21.32———13
Endocrine bone diseasesD001849——2————2
HypercalcemiaD006934HP_0003072E83.521————1
PeriodontitisD010518EFO_0000649K05.31————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic kidney failureD007676EFO_0003884N18.6————11
OsteoarthritisD010003EFO_0002506M15-M19————11
OsteonecrosisD010020EFO_0004259M87————11
Bisphosphonate-associated osteonecrosis of the jawD059266——————11
Spontaneous fracturesD005598—M84.4————11
Vitamin d deficiencyD014808EFO_0003762E55————11
OsteomalaciaD010018EFO_1002027M83————11
MortalityD009026EFO_0004352—————11
Drug therapyD004358——————11
Medication adherenceD055118EFO_0006344—————11
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTeriparatide
INNteriparatide
Description
TERIPARATIDE
Classification
Protein
Drug classpeptides: parathyroid hormone related peptide
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C
Identifiers
PDB—
CAS-ID52232-67-4
RxCUI—
ChEMBL IDCHEMBL525610
ChEBI ID—
PubChem CID16132393
DrugBankDB06285
UNII ID10T9CSU89I (ChemIDplus, GSRS)
Target
Agency Approved
PTH1R
PTH1R
Organism
Homo sapiens
Gene name
PTH1R
Gene synonyms
PTHR, PTHR1
NCBI Gene ID
Protein name
parathyroid hormone/parathyroid hormone-related peptide receptor
Protein synonyms
Parathyroid hormone 1 receptor, parathyroid hormone receptor 1, parathyroid hormone/parathyroid hormone-related protein receptor, PTH/PTHr receptor, PTH/PTHrP type I receptor, PTH1 receptor, seven transmembrane helix receptor
Uniprot ID
Mouse ortholog
Pth1r (19228)
parathyroid hormone/parathyroid hormone-related peptide receptor (Q80WU8)
Alternate
PTH2R
PTH2R
Organism
Homo sapiens
Gene name
PTH2R
Gene synonyms
PTHR2
NCBI Gene ID
Protein name
parathyroid hormone 2 receptor
Protein synonyms
parathyroid hormone receptor 2, PTH2 receptor
Uniprot ID
Mouse ortholog
Pth2r (213527)
parathyroid hormone 2 receptor (Q91V95)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Forteo – Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Teriparatide – Ligand Pharmaceuticals
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Teriparatide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 9,146 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
128,728 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use